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Adenoid cystic carcinoma (ACC) of the breast is very rare in males. There have been only eight previous articles
published on breast ACC in males. Here, we will report on the first case of this type of tumor in the Chinese
province of Hainan. The patient was a 19-year-old male, and he underwent a radical mastectomy (RM) with axillary
lymph node dissection. The histopathological examination specimen revealed that surgical margins were negative;
none of the 41 axillary lymph nodes excised were positive for malignancy. The patient is alive and well 67 months
after radical mastectomy. In the present study, we discuss the diagnosis and treatment options for male breast ACC
based on previous English publications.
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Breast adenoid cystic carcinoma (ACC), previously called
“cylindroma,” was first described by Geschickter and
Copeland [1]. It is a rare neoplasm accounting for less
than 0.1% of all patients diagnosed with breast cancer [2].
The uncommon gender (male) and rare subtype (adenoid
cystic carcinoma) of the disease make “male breast ade-
noid cystic carcinoma” exceedingly rare.
The optimal management for male breast adenoid cystic
carcinoma is unclear. Guidelines for diagnosis and treat-
ment are based on those used for female breast ACC.
We have reviewed all the cases which occurred in our
hospital from January 1994 to January 2014 and there
was only one case of male breast ACC in all that time.
This is the case of the 19-year-old patient that was
mentioned earlier.
To our knowledge, only eight previous articles deal
with breast ACC in males [3-10]. We will report the first
case in Hainan Province of this unusual tumor and its
status after 67 months of follow-up. The objective of this
article is to draw attention to the diagnosis and to the
treatment options for this tumor type.* Correspondence: guanqiaoli1981@163.com
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The patient is a 19-year-old man. The painless palpable
mass in the right chest wall was approximately 20 mm
in diameter, and he reported that the mass had persisted
for the past 4 years. The patient qualified for a biopsy in
a local county-level hospital. The pathologist then con-
firmed an adenoid cystic carcinoma. The specimen
examination showed a mixed tubular and cribriform pat-
tern. The estrogen receptor (ER) was positive at 3%. The
sample was negative for progesterone receptor (PR) and
c-erbB2. Then, he came to the thoracic surgery depart-
ment of our hospital in February 2009. Physical examin-
ation revealed a 20 mm × 21 mm size subareolar mass
which was irregularly shaped without fixation to the skin
or muscle. There was no clinical evidence of regional
lymphadenopathy. The patient had no past medical his-
tory or family history of cancer, and the patient did not
smoke or drink alcohol.
A breast ultrasound and mammography were per-
formed. The ultrasonography (USG) revealed an ir-
regular, mixed echoic, partial compressible mass
(21 mm× 20 mm× 9 mm) in the subareolar region of the
right breast (Figure 1A). Mammography (Figure 1B) re-
vealed a spiculate hyperdense lesion (30 mm× 15 mm) in
the right breast in accordance with the findings of the
ultrasonography. Serum tumor markers and other routine
blood tests were normal. The chest X-ray, bone scan,
axillary lymph node, and abdominal ultrasound werehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Ultrasonography, mammography, and histopathological examination of male breast adenoid cystic carcinoma.
(A) Ultrasonography revealed an irregular, mixed echoic, partial compressible mass in the subareolar region. (B) Mammography (mediolateral oblique)
revealed a spiculate hyperdense lesion. (C) Microscopic picture of male ACC stained by H&E stain (original magnification × 50) shows a predominant
cribriform pattern and is composed of pseudocysts, filled with basophilic mucin, surrounded by basaloid cells. Neoplastic cells were arranged in
cribriform and tubular.
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a radical mastectomy (RM) with axillary lymph node
dissection. The pathological examination of the resec-
tion specimen revealed a 30 mm × 20 mm × 15 mm
tumor. The histopathological examination specimen re-
vealed (Figure 1C) that surgical margins were negative;
none of the 41 axillary lymph nodes excised were posi-
tive for malignancy. Microscopic examination revealed
that the tumor is composed of pseudocysts, filled with
basophilic mucin, surrounded by basaloid cells. Neo-
plastic basaloid cells were arranged in cribriform and
tubular. The neoplastic cells were negative for estrogen
receptor expression, progesterone receptor expression,
and HER2/neu staining by immunohistochemistry. The
tumor was pathologically staged as pT2N0M0. Since
the estrogen receptor was 3% positive in the biopsy, it
was decided for the patient to be treated with tamoxi-
fen at a daily dose of 20 mg for 5 years. But tamoxifen
was terminated after 13 months because of sexual dys-
function. Neither chemotherapy nor radiotherapy was
performed in the present case. After 67 months of
post-operative follow-up, our patient remains free of
loco-regional recurrence or distant metastases.
Discussion
According to previous reports, ACC of the breast occurs
predominantly in older female patients, with a median
age range of 58–64 years [11]. The age distribution in
males is not clear due to the lack of data about this sub-
ject. However, according to these eight cases of male
breast ACC that have been documented [3-10], the me-
dian age at diagnosis was 37 years (range 13–82 years);
four (50%) patients were diagnosed between the ages of 10
and 29. ACC of the breast occurs predominantly in youn-
ger male patients which is different from female patients.
Male breast cancer most frequently presents as a firm,
painless breast mass, along with palpable axillary nodes,
nipple retraction, and ulceration [12]. The mass is usu-
ally located in the subareolar region, but can also beseen in the upper outer quadrant [13]. Although ACC of
the breast is also present as a subareolar mass and is
generally multifocal [14], nipple discharge is not a com-
mon presenting symptom. ACC of the breast is rarely bi-
lateral and has no tendency for a particular side of the
breast [15]. The published tumor sizes of male breast
ACC ranges from 1.8 to 3.7 cm [11]. The patient in the
present study complained of a subareolar mass (2 cm) in
the upper outer quadrant.
ACC of the breast shows pathological findings similar
to ACC of the salivary gland. ACC has three varied
growth patterns: glandular, tubular, and solid. Ro [16]
classified ACC into three grades of tumor on the basis
of the solid component as grade 1, completely glandular
and cystic; grade 2, <30% solid component; and grade 3,
>30% of solid components. All grade 3 tumors appear to
behave like high-grade ductal breast cancer.
ACC of the breast in females usually has very favorable
biological characteristics for treatment [2]. ACC of the
breast belongs to the basal-like subgroup of breast can-
cers [17]. Based on extensive molecular and genetic pro-
filing studies, basal-like tumors are most often hormone
receptor (ER and PR) negative and do not express hu-
man epidermal growth factor receptor 2 (HER2) [18,19].
Unlike other triple-negative breast cancers that are asso-
ciated with poor prognosis, breast ACC has an overall
excellent prognosis [2]. The incidents of axillary lymph
node metastases and distant metastases are lower [20]. It is
because of these distinct clinic-pathologic features that set
it apart from the other triple-negative breast cancers [11].
In the present case, immunohistochemistry (IHC) of post-
operation was negative for ER, PR, and HER2.
Guideline for diagnosis and treatment in male breast
ACC is not clear due to the extremely low levels of
cases. Surgery is a mainstay of treatment for breast
ACC. The various options for treatment include lumpec-
tomy, wide excision with or without radical radiation, or
modified radical mastectomy. Axillary lymph node dis-
section is rarely required because of the low incidence of
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breast shows that good local control can be achieved by
lumpectomy with radiation or by simple mastectomy.
Axillary lymph node dissection is worthless considering
the rarity of lymph node involvement [21]. In the
present case, a great number (41) of axillary lymph
nodes were dissected, and none of the 41 axillary lymph
nodes excised were positive for malignancy. This is very
different from previous reports. In the past, radical mast-
ectomy was preferred, and the rationale for this was the
localized lesion being close to the pectoralis major muscle
and the tumor being in a more advanced stage in men
compared to that in women at the time of diagnosis [22].
In the present days, less extensive surgery is preferred
such as modified radical mastectomy (MRM), which is an
ontologically equivalent RM [23]. In 2009, there is no in-
dependent department of breast surgery in our hospital.
The doctors in the thoracic surgery department per-
formed the breast cancer operation, but they also
performed other operations for thoracic diseases. So, their
knowledge about male breast cancer did not update fast.
And, our patient still performed radical mastectomy.
Neither adjuvant chemotherapy nor radiotherapy
guidelines have been studied clearly in patients with
ACC of the breast. Although no conclusions have been
drawn, the 2011 St. Gallen International Expert
Consensus voted that for node-negative breast ACC, ad-
juvant chemotherapy is not recommended. Radiotherapy
is administered when breast-conserving treatment is
undertaken, or a large tumor with affected lymph nodes
is present [11]. Neither the previous eight reported cases
of breast ACC in males nor our present case undertook
adjuvant chemotherapy or radiotherapy.Table 1 Summary of eight reported cases of breast adenoid c
Author Publication year Age (yr) Side Axillary lymph
node
Woyke [7] 1970 37 ? Neg
Verani [8] 1973 78 R Neg
Ferlito [9] 1974 60 L Neg
Hjorth [10] 1977 21 L Neg
Miliauskas JR [5] 1991 13 R Neg
Kshirsagar AY [3] 2006 82 L 3/5
Liu J [4] 2012 20 R 0/3
Yoo SJ [6] 2013 41 L Pos
The present case - 19 R 0/41
Summary - 10–29 years 4 L 4 Pos 2
30–49 years 2 R 4
50–70 years 1 ? 1 Neg 7
70–90 years 2
ND no axillary dissection, AD with axillary dissection, A & W alive and well, RT radiot
metastasis, “?” unknown, “pos” positive axillary lymph node, “neg” negative axillaryHormonal treatment and antiHER2 treatment are
rarely used, because hormone receptors and HER2/neu
expression are usually absent. In the view of the extreme
rarity of male ACC of the breast, it is difficult for clinical
trials. The standard treatment for male ACC of the
breast is only based on those for female breast ACC. In
the present case, tamoxifen was administered following
the operation because the estrogen receptor was 3%
positive in the biopsy. But he stopped taking tamoxifen
after 13 months because of sexual dysfunction. Since it
is a rare neoplasm, the optimal treatment and the value
of adjuvant therapy need to be further investigated.
Generally, female breast ACC has an excellent prog-
nosis compared with other forms of breast cancer and
ACC of the salivary glands [24]. Female breast ACC
does not show the aggressive characteristics of adenoid
cystic carcinoma of the salivary gland and has a low
local recurrence, a low axillary lymph node involve-
ment, and a rare distant metastasis [11]. The 10-year
survival rate for patients with ACC of the breast in fe-
males has ranged from 85% to 100% [2].
There is very little information is available on the out-
come of this tumor in the male breast ACC. However,
the prognosis of male breast ACC may not be as good
as females.
In the published cases, the follow-up period of most
breast ACC cases in males was relatively short. Our
present case is well 67 months after radical mastectomy.
Of the eight cases [3-10] in Table 1, two patients had re-
currence. And, two patients had developed multi-organ
distant metastasis. The follow-up period of two cases
was not given clearly. According to all this data, male
breast ACC seems more aggressive than female breastystic carcinoma in males
Treatment Outcome of follow-up
Local excision (ND) Recurrence at 5 and 7 year
Modified radical mastectomy (AD) DOD at 9-month lung metastase
Simple mastectomy (ND) Not available
Simple mastectomy (ND) A & W at 2 years
Subcutaneous mastectomy (ND) A & W at 30 months
Modified radical mastectomy (AD) Recurrence at 2 years
Simple mastectomy (AD) Not available
Not available Bone and lung metastasis
Radical mastectomy (AD) tamoxifen A & W at 67 months
Surgery 8 LR DM
RT 0 Yes 2 Yes 2
CT 0 No 5 No 5
HT 1 ? 2 ? 2
herapy, CT chemotherapy, HT hormone therapy, LR recurrence, DM distant
lymph node.
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reconsidered, and the treatment might be strengthened.
Conclusion
As breast ACC is a very rare tumor, especially in males,
we believe that this report will add information regard-
ing its knowledge and management.
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